Hepatitis Monthly

Published by: Kowsar

Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver

Bita Geramizadeh 1 , * and Nasibe Seirfar 2
Authors Information
1 Transplant Research Center, Department of Pathology, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Pathology, Shiraz UNiversity of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: July 01, 2015, 15 (7); e30336
  • Published Online: July 23, 2015
  • Article Type: Research Article
  • Received: May 29, 2015
  • Accepted: June 1, 2015
  • DOI: 10.5812/hepatmon30336v2

To Cite: Geramizadeh B, Seirfar N. Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver, Hepat Mon. 2015 ; 15(7):e30336. doi: 10.5812/hepatmon30336v2.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol. 2012; 7: 149[DOI][PubMed]
  • 2. Sang W, Zhang W, Cui W, Li X, Abulajiang G, Li Q. Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma. Tumor Biology. 2015; 36(5): 3881-6[DOI]
  • 3. Geramizadeh B, Boub R, Rahsaz M. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls. Indian J Pathol Microbiol. 2007; 50(3): 507-10[PubMed]
  • 4. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008; 14(27): 4300-8[PubMed]
  • 5. Satir AA. An Update on the Pathogenesis and Pathology of Hepatocellular Carcinoma. Bahrain Med Bull. 2007; 29(2): 1-8
  • 6. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005; 18(12): 1591-8[DOI][PubMed]
  • 7. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008; 132(11): 1723-8[DOI][PubMed]
  • 8. Ibrahim TR, Abdel-Raouf SM. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver. Pathol Oncol Res. 2015; 21(2): 379-87[DOI][PubMed]
  • 9. Zaakook M, Ayoub M, Sinna EA, El-Sheikh S. Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytology. J Egypt Natl Canc Inst. 2013; 25(4): 173-80[DOI][PubMed]
  • 10. Yan B, Wei JJ, Qian YM, Zhao XL, Zhang WW, Xu AM, et al. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann Diagn Pathol. 2011; 15(3): 162-9[DOI][PubMed]
  • 11. Anatelli F, Chuang ST, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008; 130(2): 219-23[DOI][PubMed]
  • 12. Krings G, Ramachandran R, Jain D, Wu TT, Yeh MM, Torbenson M, et al. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol. 2013; 26(6): 782-91[DOI][PubMed]
  • 13. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009; 34(3): 649-56[PubMed]
  • 14. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008; 21(8): 1011-8[DOI][PubMed]
  • 15. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006; 37(11): 1435-41[DOI][PubMed]
  • 16. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010; 34(8): 1147-54[DOI][PubMed]
  • 17. McKnight R, Nassar A, Cohen C, Siddiqui MT. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. Cancer Cytopathol. 2012; 120(4): 223-9[DOI][PubMed]
  • 18. Timek DT, Shi J, Liu H, Lin F. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 2012; 138(2): 203-10[DOI][PubMed]
  • 19. Fujiwara M, Kwok S, Yano H, Pai RK. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol. 2012; 120(4): 230-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments